The drugmaker will present data from the Impower110 trial at an upcoming meeting and submit the data to regulatory authorities.
Although the FDA has already approved the regimen in this indication after seeing its impact on progression-free survival, the latest data speaks to its impact on survival.
The companies will use their respective technologies to identify inhibitors of cancer-associated gene targets and optimize their use as therapeutics.
The drugmaker hopes to submit this data as part of a new drug application with the FDA later this year.
The firms plan to use Thermo Fisher's Oncomine Dx Target test to identify cancer patients with RET alterations who might benefit from Lilly's LOXO-292.
Funded projects will look at the combination of imaging and liquid biopsies for monitoring cancer patient responses and the emergence of treatment resistance.
The deal with AstraZeneca follows a licensing agreement signed earlier this year with Memorial Sloan Kettering Cancer Center also covering radionuclide PARP inhibitor IP.
The study failed to show Opdivo plus chemoradiation significantly improves PFS compared to standard of care in MGMT-methylated glioblastoma.
Out of 13 evaluable patients in the Phase II study, five saw their tumors shrink and four experienced progression-free survival for more than six months.
Researchers found that 14 percent of individuals with metastatic breast cancer had risky mutations germline mutations, including patients who did not meet testing criteria.
The cancer immunotherapy regimen and companion diagnostic test will be available in Europe for patients with triple-negative breast cancer who express PD-L1.
Data from an ongoing study suggests that the drug, combined with an androgen receptor signaling inhibitor, may be efficacious in a particularly hard to treat form of prostate cancer.
The companies will use Freenome's platform to identify cancer patients who are most likely to respond to treatment with ADC's loncastuximab tesirine.
After reviewing more than 100 studies, the panel issued recommendations focused on women with a personal or family history of BRCA1/2-related cancers or high-risk ancestry.
The two companies will work together to bring the point-of-care pretreatment diagnostic based on the XDX-01 biomarker to market in 2020.
This is the third drug the agency has approved with a pan-cancer indication.
The FDA center of excellence has engaged the technology vendor to incorporate real-world evidence into regulatory decision-making for precision oncology treatments.
Onconova will use Mission Bio's Tapestri platform to study rigosertib — a drug that Onconova is developing — to target the RAS mutation in myelodysplastic syndromes.
Progression-free survival times were comparable for EGFR-mutated non-small cell lung cancer cases treated with a combination of erlotinib and bevacizumab treatment or erlotinib.
The company will test samples from women treated with an investigational combination of AstraZeneca's PARP inhibitor olaparib and immunotherapy tremelimumab.
The test will be used to identify which metastatic, castration-resistant prostate cancer patients harbor germline BRCA mutations and will likely benefit from Lynparza.
The company has signed a new, multiyear agreement with the Korean health system to build a data sharing network to support precision cancer care in East Asia.
An updated analysis from the GioTag study supports the rationale for giving Gilotrif followed by Tagrisso in patients with EGFR Del19-positive lung cancer.
In a Phase II trial, Sophia will look for genomic markers of clinical response to ADC's treatment for relapsed or refractory diffuse large B-cell lymphoma.
The firm believes that physicians can use information from the cell-free DNA analyzed by the assay to determine whether to use anti-EGFR drugs during treatment.